Results 41 to 50 of about 24,887 (213)
Laryngoscope Investigative Otolaryngology, 2023 Background Pharyngocutaneous fistula (PCF) and salivary leaks are well known complications of head and neck surgery. The medical management of PCF has included the use of octreotide without a well‐defined understanding of its therapeutic mechanism.
Jonathan Cohen +7 more
doaj +1 more source
Octreotide acetate enhanced radio sensitivity and induced apoptosis in MCF7 breast cancer cell line
Journal of Radiation Research and Applied Sciences, 2022 Introduction: Breast cancer is the most common type of cancer among women. Radiotherapy is one of the treatment options for breast cancer; it plays a significant role in tumour control after surgery. However, radio resistance developed by tumour cells is
Alkhansa Salih Mahmoud +4 more
doaj +1 more source
Case report: Octreotide Associated Hyperkalemia [PDF]
, 2022 78-year-old female with past medical history of acromegaly status post pituitary adenoma status post resection presents to the emergency department with abdominal pain.
Schuitema, Henry +5 more
core +2 more sources
Molecular Oncology, EarlyView.This study identifies somatostatin receptor 4 (Sstr4) as a critical tumor suppressor against skin and head/neck cancers (HNSCC, cSCC, and BCC). The loss of Sstr4 removes a check on cell growth, causing hyperactivation of the MAPK‐ERK signaling pathway (↑).
Ali Taqvi +6 more
wiley +1 more source
Octreotide in the Treatment of Pancreatic Pseudocysts [PDF]
, 1996 Objective: To describe the potential use of octreotide in the treatment of pancreatic pseudocysts through a brief review of anecdotal case reports. Case Summary: Octreotide has been used in a few patients to effectively inhibit pancreatic secretions and ...
Susan E Kracke, Annie Y Lam
core +1 more source
AI‐Designed Cyclic Peptides Enable Controllable Modulation of the CD28 Immune Checkpoint
Advanced Science, EarlyView.AI‐designed cyclic peptides enable controllable modulation of the CD28 immune checkpoint through reversible disruption of CD28‐CD80/CD86 interactions. The lead peptide, CIP‐3, suppresses T‐cell activation without intrinsic agonist activity, demonstrates dose‐dependent efficacy in a murine colitis model, and attenuates inflammatory cytokine production ...
Katarzyna Kuncewicz +4 more
wiley +1 more source
Phosphorylation of sst2 receptors in neuroendocrine tumors after octreotide treatment of patients [PDF]
, 2012 Somatostatin analogues, which are used to treat neuroendocrine tumors, target the high levels of somatostatin receptor subtype 2 (SSTR1; alias sst2) expressed in these cancers.
Reubi, Jean Claude +17 more
core +1 more source
Development of a method for preparing octreotide derivative for diagnosis of neuroendocrine tumors
Бюллетень сибирской медицины, 2019 Currently the development of technologies for labeling somatostatin with technetium-99m for diagnosing radionuclide neuroendocrine tumors is under way. Somatostatin analogues are binded with technetium99m only by the preliminary addition of a chelating ...
M. S. Larkina +11 more
doaj +1 more source
Advanced Science, EarlyView.This study identifies C4 as a lead inhibitor of the Lpt system. Notably, C4 potentiates colistin activity by disrupting LPS transport and remodeling phospholipid homeostasis, revealing a functional interplay between the Lpt and Mla systems. These findings establish a mechanistic link between Lpt inhibition and membrane lipid remodeling, positioning Lpt–
Jianya Luo +6 more
wiley +1 more source
Adaptive vasodilatory response after octreotide treatment [PDF]
, 2001 Despite the suppression of glucagon release, an adaptive response aimed at maintaining vasodilatation after octreotide treatment may exist in portal hypertension.
Fa-Yauh Lee +8 more
core +1 more source